International Extranodal Lymphoma Study Group (IELSG)

3 in Phase 3

Quick facts

Phase 3 pipeline

chlorambucil (drug) · Oncology
Chlorambucil is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death.
high dose cytarabine · Oncology
High-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to cell death in rapidly dividing cells.
rituximab+chlorambucil · Oncology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while chlorambucil is an alkylating agent that interferes with DNA replication.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about International Extranodal Lymphoma Study Group (IELSG)

What is International Extranodal Lymphoma Study Group (IELSG)'s pipeline?

International Extranodal Lymphoma Study Group (IELSG) has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include chlorambucil (drug), high dose cytarabine, rituximab+chlorambucil.

Sector hub: All tracked pharma companies